For example, in our trial, 60% (6 of 10 MMRD patients) harbored JAK1 frameshift mutations involving the hotspot K860/P861 position compared with only 14.8% of patients with MMRD cancers in the TCGA EC data set (Fig 1B). Here, JAK1 is linked to cancer.